Premium
HtrA1, a potential predictor of response to cisplatin‐based combination chemotherapy in gastric cancer
Author(s) -
Catalano Vincenzo,
Mellone Pasquale,
d’Avino Alfredo,
Shridhar Viji,
Staccioli Maria Pia,
Graziano Francesco,
Giordani Paolo,
Rossi David,
Baldelli Anna Maria,
Alessandroni Paolo,
Santini Daniele,
Lorenzon Laura,
Testa Enrica,
D’Emidio Silvia,
De Nictolis Michele,
Muretto Pietro,
Fedeli Stefano Luzi,
Baldi Alfonso
Publication year - 2011
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2011.03818.x
Subject(s) - cisplatin , medicine , oncology , chemotherapy , cancer
Catalano V, Mellone P, d’Avino A, Shridhar V, Staccioli M P, Graziano F, Giordani P, Rossi D, Baldelli A M, Alessandroni P, Santini D, Lorenzon L, Testa E, D’Emidio S, De Nictolis M, Muretto P, Fedeli S L & Baldi A
(2011) Histopathology 58 , 669–678
HtrA1, a potential predictor of response to cisplatin‐based combination chemotherapy in gastric cancer Aims: HtrA1 is a member of the HtrA (high‐temperature requirement factor A) family of serine proteases. HtrA1 plays a protective role in various malignancies due to its tumour suppressive properties. The aim of this study was to determine HtrA1 expression as a predictor of chemoresponse in patients with advanced gastric cancer. Methods and results: HtrA1 expression was determined by immunohistochemistry on specimens of primary gastric cancer from 80 patients treated consecutively with cisplatin‐based combination chemotherapy. Response to chemotherapy was assessed according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria. Our population consisted of males/females [51/29; median age 64 years (range 32–82)]. A complete or partial response was observed in 71.4% [95% confidence interval (CI) 54.7–88.2], 66.7% (95% CI 47.8–85.5) and 28.6% (95 CI 11.8–45.3) of tumours showing high, medium and low HtrA1 expression, respectively. A statistically significant association between HtrA1 expression and the clinical response was observed ( P = 0.002). The median overall survival for patients with high/medium expression was 17 months compared to 9.5 months for patients with low HtrA1 expression ( P = 0.037). Conclusions: Identification of HtrA1 in gastric cancer prior to chemotherapy indicates that levels of HtrA1 could be used to predict response to platinum‐based combination therapies. Further assessment of HtrA1 expression is highly warranted in large, prospective studies.